

For Immediate Release

04 December 2013

**Amarex Founder and CEO Dr. Kazem Kazempour appointed to George Washington University's Regulatory Affairs Advisory Board**

As an expert drug and device regulatory leader, Amarex's CEO Dr. Kazem Kazempour has been appointed to the Advisory Board for George Washington University's newly established Regulatory Affairs program.

Dr. Kazempour will use his 15 years at the helm of Amarex and his 20+years as a biostatistician for the FDA and various pharmaceutical companies to provide a combined perspective from industry and FDA, to help create networks for students and graduates of the program, and to ensure the program's curriculum incorporates skills that meet today's business needs. Dr. Kazempour stated: "It is an honor and a privilege to be appointed to George Washington University's Regulatory Affairs Advisory Board , and I hope to serve as a guide for the program's mission in educating the next generation of international regulatory leaders."

GW's School of Medicine and Health Sciences recently established the Regulatory Affairs Program to prepare graduates to meet the challenges of dealing with FDA regulated products.

Dr. Daniela Drago, the Program's Director, stated that "[the Advisory Board is a] group of accomplished professionals with diverse backgrounds. They will provide key contributions to our strategic direction. Their input and expertise will enable us to keep our finger on the pulse of the industry."

Amarex is a global Contract Research Organization (CRO) that provides complete clinical product development services to bioscience companies to achieve FDA approval for their new medical products. General service categories include: 1) product development plan creation, 2) product safety and efficacy testing, and 3) applications to the FDA for marketing approval of new or improved medical products.

**Contact:**

20201 Century Blvd, 4th Floor  
Germantown, MD 20874  
USA  
+1-301-528-7000